Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07689162 · ClinicalTrials.gov registry record · Phase 2
Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia
A Phase 2 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT07689162 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 45 participants.
The verdict
NCT07689162, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Standard Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07689162
The ClinicalTrials.gov registry entry for NCT07689162 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT07689162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07689162 about?
NCT07689162 is a clinical study titled "Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia". The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.
What is the current status of trial NCT07689162?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-07. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07689162?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Standard Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07689162?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.